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Abstract: Vitamin D deficiency (VDD) is common in women with and without polycystic 
ovary syndrome (PCOS) and may be associated with metabolic and endocrine disorders  
in PCOS. The aim of this meta-analysis is to assess the associations of serum vitamin D 
levels with metabolic and endocrine dysregulations in women with PCOS, and to determine 
effects of vitamin D supplementation on metabolic and hormonal functions in PCOS patients. 
The literature search was undertaken through five databases until 16 January 2015 for both 
observational and experimental studies concerning relationships between vitamin D  
and PCOS. A total of 366 citations were identified, of which 30 were selected (n = 3182). 
We found that lower serum vitamin D levels were related to metabolic and hormonal 
disorders in women with PCOS. Specifically, PCOS patients with VDD were more likely to 
have dysglycemia (e.g., increased levels of fasting glucose and homeostatic model  
assessment-insulin resistance index (HOMA-IR)) compared to those without VDD. This 
meta-analysis found no evidence that vitamin D supplementation reduced or mitigated 
metabolic and hormonal dysregulations in PCOS. VDD may be a comorbid manifestation of 
PCOS or a minor pathway in PCOS associated metabolic and hormonal dysregulation. 
Future prospective observational studies and randomized controlled trials with repeated 
VDD assessment and better characterization of PCOS disease severity at enrollment are 
needed to clarify whether VDD is a co-determinant of hormonal and metabolic dysregulations 
in PCOS, represents a consequence of hormonal and metabolic dysregulations in PCOS or both. 
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1. Introduction 
Polycystic ovary syndrome (PCOS) [1] is the most common female endocrine disorder, affecting 
approximately 4%–18% women of reproductive age [2–5]. It is a heterogeneous androgen excess 
disorder with different degrees of reproductive and metabolic dysfunctions. Metabolic disturbances 
including insulin resistance, hyperinsulinemia and dyslipidemia, are common features in the majority of 
women with PCOS [6–12]. Women with PCOS may also be at elevated risk of vitamin D  
deficiency (VDD). In contrast to a prevalence of 20%–48% among the general adult population [13–15], 
a relative higher prevalence of VDD is observed among women with PCOS (approximately 67%–85% 
women with PCOS have VDD [16]). Additionally, positive associations of VDD with some well-known 
comorbidities of PCOS including type 2 diabetes, insulin resistance, metabolic syndrome, and 
cardiovascular diseases, are reported [17–20]. In this regard, an increasing number of studies have been 
conducted to investigate the specific relationship between vitamin D status and PCOS. Although several 
studies have suggested that lower vitamin D levels are associated with increased risk of insulin resistance 
and metabolic disturbance among women with PCOS [21,22], the current findings are inconsistent. 
Vitamin D receptors are expressed in 2776 genomic positions and modulate the expression of  
229 genes in more than 30 different tissues, such as skeleton, brain, breast, pancreas, parathyroid glands, 
immune cells, cardiomyocytes, and ovaries [23,24]. Thus, deficiency in this vitamin, in addition to its 
well-described role in calcium homeostasis and bone metabolism, may cause a wide range of  
extra-skeletal effects with impact on glucose homeostasis, cardiovascular disease, cancer, autoimmune 
diseases and psychological disorders [23,25–27]. Vitamin D may play a role in glucose metabolism by 
enhancing insulin synthesis and release, and increasing insulin receptor expression or suppression of 
proinflammatory cytokines that possibly contribute to the development of insulin resistance [28]. The 
effect of vitamin D on metabolic and reproductive dysfunctions in PCOS may be mediated by  
insulin resistance. Reproductively, insulin resistance increases hyperandrogenism through insulin 
increasing ovarian androgen production, and reducing sex hormone-binding globulin (SHBG) 
production [29]. Metabolically, insulin resistance is associated with an increased risk for impaired 
glucose tolerance, type 2 diabetes mellitus and cardiovascular disease [30–34]. Therefore, vitamin D 
may play a key role in the development of PCOS. 
Associations of vitamin D status with PCOS, metabolic and hormonal dysfunctions in PCOS  
in particular, have been investigated by a large number of studies, but the relationship between them 
remains inconclusive. In spite of a growing number of intervention studies assessing effects of  
vitamin D supplementation on PCOS, a lack of convincing evidence demonstrating a causal link between 
low vitamin D levels and PCOS exists, mainly due to small sample sizes (the majority of them has a 
sample size less than 30). Therefore, the objective of this systematic review and meta-analysis is to 
quantitatively summarize existing evidence to determine whether serum vitamin D concentrations are 
lower in women with PCOS compared to women without PCOS, to determine whether vitamin D 
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deficiency is associated metabolic and endocrine dysregulations in women with PCOS, and to evaluate 
effects of vitamin D supplementation on the mitigation of metabolic and hormonal functions in women 
with PCOS. 
2. Materials and Methods 
2.1. Search Strategy 
Relevant studies were identified from the following electronic databases: PubMed, Web of Science, 
Cochrane Central Register of Controlled Trials (CENTRAL), Cumulative Index to Nursing and Allied 
Health (CINAHL), and PsycINFO. Databases were searched using the search strategy as shown in 
Supplementary Table S1, from the earliest available date to 16 January 2015. We also manually searched 
reference lists of all eligible articles and previous reviews on relevant topics for additional studies. 
2.2. Study Selection  
Studies were included in the review if they fulfilled the following criteria: (1) published in the  
English language; (2) included women with PCOS; (3) presented (3.1) comparison of serum vitamin D 
concentrations between women with and without PCOS; (3.2) comparison of metabolic or endocrine 
parameters between VDD and non-VDD groups, between vitamin D intervention and placebo groups, 
or between pre- and post-intervention of vitamin D supplementation; or (3.3) correlation between 
25(OH)D and metabolic or endocrine indices in women with or without PCOS. 
Studies were excluded from this meta-analysis if they were publications from meetings/congress or 
were genetic studies that did not provide baseline descriptions of metabolic or endocrine parameters. For 
studies with more than one article based on the same study population, inclusion was limited to the one 
with the most recent publication date or with the largest sample size.  
2.3. Data Extraction 
Two reviewers (C.H. and Z.L.) independently identified and selected articles that met the  
inclusion criteria. Discrepancies were resolved by consensus and arbitration (C.H., Z.L., and A.E.E.). 
General characteristics of the study (e.g., author, year of publication, study location), characteristics of 
the study population (e.g., recruitment source, sample size, mean age and body mass index (BMI)), definition 
of PCOS, measurement of variables of interest (e.g., serum vitamin D levels; metabolic parameters, such as 
fasting glucose, fasting insulin, homeostatic model assessment-insulin resistance index (HOMA-IR), 
homeostatic model assessment-β-cell functions (HOMA-β), quantitative insulin sensitivity check  
index (QUICKI), total cholesterol, triglycerides, high density lipoprotein cholesterol (HDL-C), low 
density lipoprotein cholesterol (LDL-C), C-reactive protein (CRP); and endocrine indicators including 
total testosterone, free testosterone, free androgen index (FAI), sex hormone-binding globulin (SHBG), 
and dehydroepiandrosterone sulfate (DHEAS)) were extracted from included studies.  
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2.4. Quality Assessment 
The quality of studies was examined and controlled in accordance with checklists of Preferred 
Reporting Items for Systematic reviews and Meta-Analyses for randomized trials [35], and checklists of 
Meta-analysis of Observational Studies in Epidemiology (MOOSE) for observational studies [36]. No 
scoring methods were utilized for assessment of quality of studies due to a lack of reliable and 
standardized scales for observational studies [37–39]. 
2.5. Data Analysis 
We calculate five types of effect sizes in this study: (1) standardized mean differences (SMDs) in 
serum vitamin D levels between PCOS and non-PCOS groups; (2) SMDs in metabolic and endocrine 
indices between VDD and non-VDD groups; (3) correlations between 25(OH)D and metabolic or 
endocrine parameters; (4) pre- versus post-intervention SMDs in vitamin D concentrations, metabolic 
and endocrine parameters; and (5) post-intervention SMDs in vitamin D levels, metabolic and endocrine 
parameters between vitamin D supplementation and placebo groups. The size of the SMD can be 
interpreted as being small (<0.2), medium (0.2–0.8), or large (>0.8) [40]. Correlation values of less  
than 0.1, of 0.1–0.5, of greater than 0.5, are considered to be indicative of small, medium and large  
effect size, respectively [40]. If a study presented analyses stratified by certain key variables such  
as BMI, stratified estimates were assumed to be independent of each other and included as a separate 
unit of observation in the meta-analysis. For example, Panidis et al. performed stratified comparisons of 
serum vitamin D concentrations according to BMI values (i.e., obese PCOS vs. obese controls, 
overweight PCOS vs. overweight controls, normal weight PCOS vs. normal weight controls) [41], and 
thus three observations were obtained from this study. In order to adjust for bias resulting from small 
sample sizes, between-group SMDs were calculated using Hedges’ formula [42]. Papers which did not 
present the mean and standard deviation (SD), values of median (m) and range (a and b represent low 
and high end of range, respectively) were converted into mean and SD based on formulas as follows:  
?̅?𝑥 ≈
𝑎𝑎+2𝑚𝑚+𝑏𝑏
4
,  𝑆𝑆2 ≈ 1
12
�
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+ (𝑏𝑏 − 𝑎𝑎)2�  [43], where ?̅?𝑥 and 𝑆𝑆2 refer to the values of mean and 
variance, respectively. Correlations between serum 25(OH)D levels and metabolic and hormonal 
parameters, were also summarized in this study. Because data for some variables in the original studies 
were log-transformed, Pearson correlation coefficients were converted into Spearman correlation 
coefficients according to the formula: rs=
6
𝜋𝜋
𝑠𝑠𝑠𝑠𝑠𝑠−1(𝑟𝑟
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) , where 𝑟𝑟𝑠𝑠  and 𝑟𝑟  are Spearman and Pearson  
correlation coefficients, respectively [44]. The sampling distribution of Spearman correlation coefficients 
is problematic because its standard error (SE) depends on the value of the correlation coefficient. Thus, 
a Fisher transformation formula showed as follows was used to convert each 𝑟𝑟𝑠𝑠 into an approximately 
normally distributed variable  𝑧𝑧 with 𝑆𝑆𝑆𝑆 = 1
√𝑛𝑛−3
 (n is the sample size): 𝑧𝑧 = 1
2
(ln(1 + 𝑟𝑟𝑠𝑠) − ln(1 − 𝑟𝑟𝑠𝑠)). 
After appropriate conversion, the inverse variance-weighted method was used to estimate effect size and 
corresponding 95% confidence intervals (CIs). The Fisher-transformed data were converted back to the 
original scale for interpretation. Heterogeneity across studies was tested using Cochran’s Q and I2 
statistic [45]. A p-value less than 0.1 from the Q statistic was considered to be indicative of statistically 
significant heterogeneity. The I2 statistic was calculated to express the fraction of variation between 
studies that was due to heterogeneity [45]. I2 values of 25%, 50% and 75% were considered as low, 
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moderate and high heterogeneity, respectively [45]. The pooled effect size was estimated based on the 
fixed effects model when no significant heterogeneity was detected. Otherwise, a random effects model 
was used [46]. Sensitivity analyses in which one study at a time was omitted from the effect size 
calculations were undertaken to determine whether the pooled effect size was unduly influenced by a 
specific study. Publication bias was examined using a funnel plot and Egger’s test [47]. All analyses were 
performed in STATA 12 (StataCorp, College Station, TX, USA). p-Values < 0.05 were considered 
statistically significant for all analyses except heterogeneity tests. 
3. Results 
3.1. Study Selection 
The search yielded 365 citations as shown in Figure 1. Initial screening of the title and abstract 
resulted in the exclusion of 179 references and 77 studies proceeded to detailed evaluation. One 
additional reference [48] was identified by searching the reference lists of the 77 full text papers. After 
further examination, 30 studies met the inclusion criteria and were included in the meta-analysis. 
 
Figure 1. Flowchart of literature search. 
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3.2. Characteristics of Included Studies 
A total of 30 studies involving 3182 participants were included in the meta-analysis. Characteristics of 
included studies are presented in Table 1. Twenty-five studies defined PCOS based on criteria of Rotterdam 
European Society for Human Reproduction & Embryology/American Society for Reproduction Medicine 
(ESHRE/ASRM) PCOS Consensus Workshop Group [1], while five studies diagnosed PCOS using the 
National Institutes of Health criterion [49]. Eleven studies were conducted in Europe, ten in Asia, three 
in U.S., three in Turkey, and three in Egypt. Thirteen studies compared 25(OH)D and/or 1,25(OH)2D 
levels between women with or without PCOS; five studies compared metabolic or hormonal parameters 
between VDD and non-VDD groups; twelve studies presented correlation coefficients between 25(OH)D 
and metabolic/endocrine indices among women with PCOS; ten studies compared biochemical outcomes 
between pre- and post-intervention of vitamin D supplementation; and six studies compared  
post-intervention differences in metabolic and endocrine parameters between vitamin D supplementation 
and placebo groups. 
3.3. Differences in Vitamin D Levels between PCOS Patients and Controls 
Among thirteen studies comparing 25(OH)D levels between women with and without PCOS, two 
presented stratified statistics in terms of BMI values [41,50], therefore yielding a total of 16 observations 
for calculation of effect size for 25(OH)D levels. A random effects model revealed a moderate estimate 
of effect size (SMD: −0.74, 95% CI: −1.26 to −0.22) (Figure 2, top), which indicated that serum 
25(OH)D concentrations were significantly lower in PCOS patients compared to controls without PCOS. 
Significant heterogeneity was identified across included studies (p < 0.001, I2 = 96.5%). Sensitivity 
analyses were conducted to assess the extent to which individual studies with extremely large SMDs 
influenced the pooled SMD. No substantially influential test was identified from the sensitivity analyses. 
Omitting two studies [48,51] with small sample size (<30) resulted in insignificant estimates of SMD 
(−0.50; 95%CI: −1.03 to 0.03). Egger’s test (p = 0.298) and visual examination of funnel plots indicated 
no significant publication bias over all included studies. 
Three studies involving five observations were included in the estimate of effect size for 1,25(OH)2D. 
Heterogeneity between studies was statistically significant (p = 0.091, I2 = 50.1%). No significant 
difference in 1,25(OH)2D was found between PCOS patients and controls (SMD: 0.18; 95%CI: −0.10 
to 0.45) (Figure 2, bottom). The Funnel plot and Egger’s test (p = 0.453) suggested no significant 
publication bias over the included studies. 
3.4. Comparison in Metabolic and Endocrine Indices in PCOS between VDD and Non-VDD Women 
Being vitamin D deficient was significantly associated with lower HDL-C, and with higher fasting 
glucose, fasting insulin, HOMA-IR, HOMA-β, and FAI among women with PCOS (Table 2). No 
significant heterogeneity was found in studies reporting fasting glucose, fasting insulin, HOMA-β,  
HDL-C, LDL-C and FAI. No significant publication bias was identified from all reported parameters. 
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Table 1. Characteristics of included studies in the meta-analysis. 
Author (Year) Location Diagnosis Participants (n) Variables 
Comparison between PCOS Patients and Control Women 
Panidis et al., (2005) [41] Greece ESHRE/ASRM PCOS,(291); healthy CTRL,(109) 25(OH)D; 1,25(OH)2D 
Mahmoudi et al., (2010) [52] Iran NIH PCOS, (85); CTRL, (115)  25(OH)D; 1,25(OH)2D 
Li et al., (2011) [53] UK ESHRE/ASRM PCOS, (25); CTRL, (27) 25(OH)D 
Savastano et al., (2011) [50] Italy ESHRE/ASRM PCOS, (90); Healthy CTRL, (40) 25(OH)D 
Hassan et al., (2012) [48] Egypt ESHRE/ASRM PCOS, (30); CTRL, (15) 25(OH)D 
Lin et al., (2012) [54] Taiwan ESHRE/ASRM PCOS, (188); CTRL, (143) 25(OH)D 
Mazloomi et al., (2012) [55] Iran ESHRE/ASRM PCOS, (103); healthy CTRL, (103) 25(OH)D 
Nestler et al., (2012) [51] USA NIH Obese PCOS, (8); Obese CTRL, (9) 25(OH)D; 1,25(OH)2D 
Tsakova et al., (2012) [56] Bulgaria ESHRE/ASRM Obese PCOS, (20); Obese CTRL, (33) 25(OH)D 
El-Shal et al., (2013) [57] Egypt ESHRE/ASRM PCOS, (150); CTRL, (150) 25(OH)D 
Guducu et al., (2014) [58] Turkey ESHRE/ASRM PCOS, (58); CTRL, (38) 25(OH)D 
Ghadimi et al. (2014) [59] Iran ESHRE/ASRM PCOS, (104); CTRL, (88) 25(OH)D 
Sahin et al. (2014) [60] Turkey ESHRE/ASRM Lean PCOS, (50); CTRL (40) 25(OH)D 
Comparison between Vitamin D Deficient and Non-Deficient PCOS Patients 
Wehr et al., (2009) [22] Austria ESHRE/ASRM PCOS, (206) 
FG; HOMA-IR; HOMA-β; QUICKI; FI; TC; TG; 
HDL-C; LDL-C; CRP; TT; FT; SHBG; FAI 
Li et al., (2011) [53] UK ESHRE/ASRM PCOS, (25) 
FG; FI; HOMA-IR; HOMA-β; QUICKI; TC; 
HDL-C; LDL-C; TG; CRP; TT; SHBG; FAI 
Patra et al., (2012) [61] India ESHRE/ASRM PCOS, (60) HOMA-IR 
Bhattacharya et al., (2013) [62] India ESHRE/ASRM PCOS, (93) TT; SHBG; FAI; FG; FI 
Velija-Asimi et al., (2014) [63] 
Bosnia and 
Herzegovina 
ESHRE/ASRM PCOS, (60) TC; TG; CRP; FG; FI; TT; HOMA-IR; SHBG 
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Table 1. Cont. 
Author (Year) Location Diagnosis Participants (n) Variables 
Correlation between 25(OH)D and Metabolic and Endocrine Parameters among Women with PCOS 
Hahn et al., (2006) [64] Germany NIH PCOS, (120) 
HOMA-IR; HOMA-β; QUICKI; TG; HDL-C; 
LDL-C; FG; TT;FAI; SHBG; DHEAS 
Wehr et al., (2009) [22] Austria ESHRE/ASRM PCOS, (206) 
FG; HOMA-IR; FI; TC; TG; HDL-C; LDL-C; 
CRP; TT; FT; SHBG; FAI 
Yildizhan et al., (2009) [65] Turkey ESHRE/ASRM PCOS, (100) HOMA-IR; TC; TG; TT; DHEAS;  
Li et al., (2011) [53] UK ESHRE/ASRM PCOS, (25) 
FG; FI; HOMA-IR; HOMA-β; QUICKI; TC; 
HDL-C; LDL-C; TG; CRP; TT; SHBG; FAI 
Savastano et al., (2011) [50] Italy ESHRE/ASRM PCOS, (90) HOMA-IR; FI; FAI 
Bonakdaran et al., (2012) [66] Iran ESHRE/ASRM PCOS, (51) DHEAS 
Patra et al., (2012) [61] India ESHRE/ASRM PCOS, (60) HOMA-IR; FG 
El-Shal et al., (2013) [57] Egypt ESHRE/ASRM PCOS, (150) 
TC; TG; HDL-C; LDL-C; FG; FI; HOMA-IR; 
HOMA-β; QUICKI; TT; FT; SHBG; DHEAS 
Guducu et al., (2014) [58] Turkey ESHRE/ASRM PCOS, (58) FI 
Kozakowski et al. (2014) [67] Poland ESHRE/ASRM Obese PCOS, (60) 
TC; HDL-C; LDL-C; TG; FG; FI; TT; DHEAS; 
FAI; SHBG 
Ghadimi et al. (2014) [59] Iran ESHRE/ASRM PCOS, (104) HOMA-IR 
Sahin et al. (2014) [60] Turkey ESHRE/ASRM Lean PCOS, (50) HOMA-IR 
Comparison between Post- and Pre-Intervention of Vitamin D 
Kotsa et al., (2009) [68] Greece ESHRE/ASRM Obese PCOS, (15) TC; TG; HDL-C; LDL-C 
Selimoglu et al., (2010) [69] Turkey ESHRE/ASRM PCOS, (11) 
FG; FI; HOMA-IR; 25/(OH)D; TT; FT;  
SHBG; DHEAS 
Wehr et al., (2011) [70] Austria ESHRE/ASRM PCOS, (52) 
FG; FI; HOMA-IR; HOMA-β; TC; TG; HDL-C; 
LDL-C; FT; SHBG; TT; FAI; 25(OH)D 
  
 
Nutrients 2015, 7 4563 
 
Table 1. Cont. 
Author (Year) Location Diagnosis Participants (n) Variables 
Comparison between Post- and Pre-Intervention of Vitamin D 
Ardabili et al., 2012 [71] Iran ESHRE/ASRM PCOS and vitamin D deficiency, (50) FG; FI; HOMA-IR; HOMA-β; QUICKI 
Bonakdaran et al., (2012) [66] Iran ESHRE/ASRM PCOS, (51) FG; FI; HOMA-IR; TT; DHEAS; 25(OH)D 
Pal et al., (2012) [72] USA ESHRE/ASRM Overweight PCOS, (12) FG; FI; QUICKI; TT; SHBG; FAI; 25(OH)D 
Rahimi-Ardabili et al., (2013) [73] Iran ESHRE/ASRM PCOS and vitamin D deficiency, (50) TC; TG; HDL-C; LDL-C; 25(OH)D 
Asemi et al. (2014) [74] Iran ESHRE/ASRM Overweight or obese PCOS, (52) 
25(OH)D; FG; FI; HOMA-IR; QUICKI; TG; TC; 
LDL-C; HDL-C 
Raja-Khan et al., (2014) [75] USA NIH PCOS, (28) 
FG; FI; QUICKI; HOMA-IR; TC; HDL-C;  
LDL-C; TG; TT; FT; 25(OH)D 
Tehrani et al. (2014) [76] Iran NIH PCOS, (40) 25(OH)D 
Post-Intervention of Vitamin D Compared to Post-Intervention of Placebo 
Ardabili et al., 2012[71] Iran ESHRE/ASRM PCOS and vitamin D deficiency, (50) FG; FI; HOMA-IR; HOMA-β; QUICKI 
Bonakdaran et al., (2012) [66] Iran ESHRE/ASRM PCOS, (51) FG; FI; HOMA-IR; TT; DHEAS; 25(OH)D 
Rahimi-Ardabili et al., (2013) [73] Iran ESHRE/ASRM PCOS and vitamin D deficiency, (50) TC; TG; HDL-C; LDL-C; 25(OH)D 
Asemi et al. (2014) [74] Iran ESHRE/ASRM Overweight or obese PCOS, (52) 
25(OH)D; FG; FI; HOMA-IR; QUICKI; TG; 
LDL-C; HDL-C 
Raja-Khan et al., (2014) [75] USA NIH PCOS, (28) 
FG; FI; QUICKI; HOMA-IR; TC; HDL-C;  
LDL-C; TG; TT; FT; 25(OH)D 
Tehrani et al. (2014) [76] Iran NIH PCOS, (40) 25(OH)D 
PCOS: polycystic ovary syndrome; CTRL: control; 25(OH)D: 25-hydroxyvitamin D; 1,25(OH)2D: 1,25-dihydroxyvitamin D; FG: fasting glucose; FI: fasting insulin; 
HOMA-IR: homeostatic model assessment-insulin resistance index; HOMA-β:homeostatic model assessment- β-cell functions ; QUICKI: quantitative insulin sensitivity 
check index; TC: total cholesterol; HDL-C: high density lipoprotein cholesterol; LDL-C: low density lipoprotein cholesterol; TG: triglycerides; TT: total testosterone; FT: 
free testosterone; CRP: C-reactive protein; FAI: free androgen index; SHBG: sex hormone-binding; DHEAS: dehydroepiandrosterone sulfate; ESHRE/ASRM: European 
Society for Human Reproduction & Embryology/American Society for Reproduction Medicine. 
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Figure 2. Forest plots showing the effect size of the association between serum vitamin D 
levels and PCOS in women (SMD, standardized mean difference; OBS, obese; OVW, 
overweight; NMW, normal weight; PCOS, polycystic ovary syndrome; CTRL, control.). 
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3.5. Correlation of 25(OH)D with Metabolic and/or Endocrine Parameters 
As shown in Table 2, serum 25(OH)D concentrations were negatively correlated with fasting glucose, 
fasting insulin, triglycerides, CRP, FAI and DHEAS among women with PCOS. Positive correlations 
between 25(OH)D and QUICKI, HDL-C, and SHBG, were found. Significant heterogeneity was 
identified from parameters including fasting glucose, HOMA-IR, total cholesterol, HDL-C,  
LDL-C, triglycerides, total testosterone, free testosterone and DHEAS. To investigate unduly  
influential studies, a sensitivity analysis was performed on parameters that showed substantial  
between-study heterogeneity and had been reported by five or more included studies (data not shown). 
When excluding the study conducted by Yildizhan et al. [65], no significant changes were detected in 
either pooled effect size estimate (r: −0.26; 95% CI: −0.36 to −0.15) or between-study heterogeneity  
(p = 0.027, I2 = 53.8%) over studies reporting HOMA-IR. Similarly, no substantially influential studies 
were identified among those reporting fasting glucose, total cholesterol, HDL-C, LDL-C and FAI in 
terms of results of sensitivity tests. For studies reporting triglycerides, omitting the study by  
Yildizhan et al. [65] led to substantial change in heterogeneity test (p = 0.325, I2 = 14.0%), but not in 
the estimate of effect size (r: −0.20; 95%CI: −0.30 to −0.10). Likewise, a significant change was 
identified in the heterogeneity test for total testosterone by removing observations obtained by  
Yildizhan et al. [65]. Four studies reported correlation coefficients of 25(OH)D with biochemical  
parameters [53,57,58,60] among non-PCOS controls. We found negative correlations between 25(OH)D 
levels and fasting insulin, HOMA-IR, CRP. Additionally, QUICKI was found to be positively correlated 
with 25(OH)D levels (data not shown). 
3.6. Comparison between Post- and Pre-Intervention of Vitamin D Supplementation 
Triglyceride levels in PCOS patients were significantly decreased, and blood 25(OH)D levels were 
significantly increased after treatment with vitamin D (Table 2). Substantially statistical heterogeneity 
was found among included studies reporting 25(OH)D, but no extremely influential studies were 
identified in terms of sensitivity tests. No significant publication bias was found in all reported 
parameters except triglycerides. 
3.7. Post-Intervention of Vitamin D Compared to Post-Intervention of Placebo 
Fasting insulin levels in PCOS patients were significantly higher in vitamin D intervention group 
compared to placebo group (Table 2). No significant differences were found in other metabolic 
parameters and serum 25(OH)D levels between treatment and placebo groups. No significant publication 
bias was found among reported parameters. 
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Table 2. Meta-analysis results. 
Outcome No. of Studies No. of Observations SMD (95%CI) ‡ 
Heterogeneity Test Publication Bias 
p-Value I2 (%) p-Value 
Comparison between Vitamin D Deficient and Non-Deficient PCOS Patients 
Fasting glucose 4 5 0.31 (0.10, 0.53) 0.429 0.0 0.254 
Fasting insulin 4 5 0.63 (0.42, 0.85) 0.146 41.3 0.077 
HOMA-IR 4 5 1.11 (0.51, 1.71) 0.002 76.5 0.130 
HOMA-β 2 3 0.43 (0.15, 0.71) 0.183 41.1 0.613 
QUICKI 2 3 −0.63 (−1.28, 0.03) 0.069 62.6 0.207 
Total cholesterol 3 4 −0.14 (−0.67, 0.40) 0.026 67.7 0.767 
HDL-C 2 3 −0.58 (−0.86, −0.30) 0.379 0.0 0.673 
LDL-C 2 3 −0.11 (−0.39, 0.16) 0.101 56.3 0.658 
Triglycerides 3 4 −0.17 (−1.33, 0.99) <0.001 92.7 0.657 
CRP 3 4 0.12 (−0.67, 0.92) <0.001 85.2 0.757 
Total testosterone 4 4 0.08 (−0.28, 0.60) 0.075 56.5 0.576 
SHBG 4 4 0.16 (−0.28, 0.60) 0.018 70.1 0.656 
FAI 3 3 0.25 (0.01, 0.48) 0.385 
0.
0 
0.281 
Correlation between 25(OH)D and Metabolic and Endocrine Parameters among Women with PCOS 
Fasting glucose 6 6 −0.23 (−0.38, −0.07) 0.009 67.2 0.287 
Fasting insulin 6 6 −0.29 (−0.37, −0.21) 0.274 21.2 0.410 
HOMA-IR 9 10 −0.52 (−0.23, 0.72) <0.001 95.9 0.153 
HOMA-β 3 3 −0.01 (−0.13, 0.11) 0.351 
4.
4 
0.335 
QUICKI 3 3 0.19 (0.07, 0.30) 0.467 
0.
0 
0.036 
Total cholesterol 5 6 −0.05 (−0.30, 0.21) <0.001 84.4 0.812 
HDL-C 5 5 0.35 (0.22, 0.47) 0.079 52.2 0.955 
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Table 2. Cont. 
Outcome No. of Studies No. of Observations SMD (95%CI) ‡ 
Heterogeneity Test Publication Bias 
p-Value I2 (%) p-Value 
Correlation between 25(OH)D and Metabolic and Endocrine Parameters among Women with PCOS 
LDL-C 5 5 −0.06 (−0.33, 0.21) <0.001 86.4 0.762 
Triglycerides 6 7 −0.69 (−0.91, −0.16) <0.001 98.4 0.272 
CRP 3 3 −0.28 (−0.37, −0.18) 0.550 0.0 0.530 
Total testosterone 5 6 −0.65 (−0.94, 0.18) <0.001 98.8 0.422 
SHBG 5 5 0.31 (0.23, 0.39) 0.179 36.4 0.815 
FAI 5 5 −0.22 (−0.31, −0.12) 0.099 48.8 0.406 
Free testosterone 2 2 −0.14 (−0.41, −0.15) 0.007 86.1 NA 
DHEAS 5 6 −0.68 (−0.90, −0.17) <0.001 97.6 0.259 
Comparison between Post- and Pre-Intervention of Vitamin D 
Fasting glucose 7 7 −0.14 (−0.37, 0.09) 0.285 19.0 0.101 
Fasting insulin 7 7 −0.02 (−0.25, 0.21) 0.838 0.0 0.722 
HOMA-IR 6 6 −0.05 (−0.29, 0.19) 0.692 0.0 0.644 
HOMA-β 3 3 0.16 (−0.12, 0.44) 0.767 0.0 0.953 
QUICKI 4 4 −0.07 (−0.39, 0.26) 0.762 0.0 0.579 
Total cholesterol 5 5 0.01 (−0.24, 0.26) 0.374 5.7 0.643 
HDL-C 5 5 0.03 (−0.22, 0.27) 0.768 0.0 0.174 
LDL-C 4 4 0.10 (−0.17, 0.38) 0.312 0.0 0.577 
Triglycerides 4 4 −0.45 (−0.73, −0.17) 0.607 0.0 0.002 
Total testosterone 5 5 −0.07 (−0.35, 0.21) 0.844 0.0 0.732 
SHBG 3 3 −0.16 (−0.49, 0.17) 0.729 0.0 0.706 
FAI 2 2 −0.14 (−0.49, 0.22) 0.429 0.0 NA 
Free testosterone 3 3 −0.17 (−0.50, 0.16) 0.416 0.0 0.649 
DHEAS 2 2 0.16 (−0.39, 0.70) 0.492 0.0 NA 
25(OH)D 7 7 2.09 (1.28, 2.91) <0.001 85.5 0.201 
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Table 2. Cont. 
Outcome No. of Studies No. of Observations SMD (95%CI) ‡ 
Heterogeneity Test Publication Bias 
p-Value I2 (%) p-Value 
Post-Intervention of Vitamin D Compared to Post-Intervention of Placebo 
Fasting glucose 4 4 0.27 (−0.04, 0.58) 0.210 33.7 0.811 
Fasting insulin 4 4 0.14 (−0.14, 0.45) 0.116 49.3 0.513 
HOMA-IR 4 4 0.25 (−0.07, 0.56) 0.760 0.0 0.440 
QUICKI 3 3 −0.14 (−0.48, 0.21) 0.710 0.0 0.254 
HDL-C 3 4 0.22 (−0.22, 0.66) 0.095 52.9 0.392 
LDL-C 3 3 −0.11 (0.46, 0.23) 0.799 0.0 0.133 
Triglycerides 3 3 −0.04 (−0.38, 0.31) 0.474 0.0 0.474 
Total testosterone 2 2 −0.09 (−0.60, 0.42) 0.404 0.0 NA 
25(OH)D 5 5 2.11 (0.85, 3.37) <0.001 79.5 0.177 
25(OH)D: 25-hydroxyvitamin D; HOMA-IR: homeostatic model assessment-insulin resistance index; HOMA-β: homeostatic model assessment- β-cell functions ; QUICKI: 
quantitative insulin sensitivity check index; TC: total cholesterol; HDL-C: high density lipoprotein cholesterol; LDL-C: low density lipoprotein cholesterol; CRP: C-reactive protein; 
FAI: free androgen index; SHBG: sex hormone-binding; DHEAS: dehydroepiandrosterone sulfate. For comparisons between vitamin D deficient and non-deficient groups, 
SMD < 0 suggests a negative association with vitamin D deficiency, SMD > 0 indicates a positive association with vitamin D deficiency. For correlations of 25(OH)D with 
metabolic and endocrine parameters among women with PCOS, SMD < 0 suggests a negative correlation with 25(OH)D; SMD > 0 indicates a positive correlation  
with 25(OH)D. For comparisons between post- and pre-intervention of vitamin D, SMD < 0 suggests a negative effect of vitamin D supplementation, SMD>0 indicates a 
positive effect of vitamin D supplementation. For comparisons between post-invention of vitamin D and placebo groups, SMD < 0 suggests a negative effect of  
vitamin D supplementation, SMD > 0 indicates a positive effect of vitamin D supplementation. 
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4. Discussion 
4.1. Principal Findings and Interpretations 
The present review and meta-analysis supports that serum vitamin D status is related to metabolic 
and hormonal dysfunctions in women with PCOS. Among women with PCOS, those with vitamin D 
deficiency were more likely to have measures of dysglycemia compared to those without vitamin D 
deficiency. Similarly, lower vitamin D levels were positively correlated with markers of dysglycemia, 
support a significant difference in serum vitamin D levels between women with and without PCOS.  
In addition, we found no significant improvement in metabolic and hormonal functions among women 
with PCOS supplemented with vitamin D. 
Metabolic disturbance is not uncommon in women affected by PCOS, with a prevalence of insulin 
resistance ranging from 50% to 70% [77–79], and up to 70% for dyslipidemia [10]. Dysglycemia  
and dyslipidemia, regular types of nutritional and metabolic disorders, are associated with elevated 
prevalence of insulin resistance, impaired glucose tolerance, metabolic syndrome, type 2 diabetes, and 
cardiovascular disease. A meta-analysis conducted by Moran et al. demonstrated that PCOS is associated 
with a higher prevalence of impaired glucose tolerance (OR: 2.48; 95% CI: 1.63 to 3.77), type 2 diabetes 
mellitus (OR: 4.43; 95% CI: 4.06 to 4.82), and metabolic syndrome (OR: 2.88; 95% CI: 2.40 to 3.45) [80]. 
Another meta-analysis revealed that the risk of cardiovascular disease was higher among women with 
PCOS compared to non-PCOS controls (RR:2.02; 95%CI: 1.47 to 2.76) [17]. Recently, the potential 
causes of metabolic dysregulation in PCOS have been the subject of intense scholarly debate. Serum 
vitamin D status has been proposed as a missing link between metabolic dysregulation and PCOS. The 
role of vitamin D on PCOS and its possible implication for metabolic dysfunctions among women with 
PCOS has been extensively studied in recent years. A body of evidence suggests that a low vitamin D 
level is related to elevated levels of HOMA-IR, total cholesterol, LDL-C, glucose, CRP, triglycerides, 
and decreased HDL-C, QUICKI in women affected by PCOS [22,48,52,53,57,58,65]. In agreement with 
these findings, the present study reports inverse associations of serum vitamin D concentrations with 
HOMA-IR, CRP, triglycerides, and positive associations with HDL-C, QUICKI.  
Hyperandrogenism, one of the primary symptoms of PCOS, is characterized by excessive levels of 
androgens in the body. It is reported that approximately 75% of PCOS patients have hyperandrogenism, 
and more than 80% of which demonstrate supranormal levels of free testosterone [81]. Serum DHEAS, 
testosterone, SHBG and FAI are used as diagnostic markers of hyperandrogenism. There is evidence 
suggesting that low serum vitamin D levels are associated with abnormalities in markers of 
hyperandrogenism. For instance, some studies report inverse associations between serum 25(OH)D 
levels and testosterone, DHEAS and FAI and SHBG among with PCOS [22,53,63–65,72]. Consistent 
results were obtained from the present study. 
VDD is common among women with PCOS [16], but the present meta-analysis does not demonstrate 
significantly lower levels of vitamin D among women with PCOS compared to non-PCOS controls.  
This finding, however, should be interpreted with caution. Through a close examination of included 
studies in this review, we find substantially varied prevalence of VDD among women with PCOS. A 
recent observational study by Velija-Asimi et al. found that 68% (41 out of 60) PCOS patients had VDD, 
of which 54% (n = 22) were obese and 46% were non-obese (n = 19) [63]. Another study also reported a 
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higher prevalence of VDD in obese women with PCOS than in lean women with PCOS (70% vs. 60%) [56]. 
These studies suggest that the risk of VDD is associated with comorbidities among women with PCOS. 
That is, incidence of VDD is dependent upon severity of PCOS. Therefore, assessment of prevalence of 
VDD regardless of development stage of PCOS may be responsible for the insignificant difference in  
vitamin D status between PCOS and non-PCOS groups. 
Epidemiologic studies suggest that low vitamin D levels are related to impaired glucose clearance, 
insulin secretion, and insulin resistance [82–87]. It is known that vitamin D affects glucose metabolism 
and may play a role in the development of subsequent metabolic and endocrine disorders in women  
with PCOS. Our study identified eight studies that investigated the effects of vitamin D therapy on metabolic 
and/or endocrine parameters on women with PCOS [66,68–73,75]. The results of this study suggest that 
supplementation of vitamin D does not significantly improve metabolic (except triglycerides) and endocrine 
features in PCOS patients. Similarly, no significant differences in metabolic parameters (except fasting 
insulin) were found between vitamin D supplementation and placebo groups. If a causal  
relationship exists, intervention of vitamin D is supposed to result in mitigation of metabolic and 
hormonal features in PCOS. In this regard, it is questionable that there is a cause-effect relationship 
between VDD and PCOS.  
4.2. Strengths and Limitations 
This study is the first meta-analysis summarizing evidence of the roles of vitamin D on metabolic and 
hormonal features in women with PCOS. The primary strength of this meta-analysis is the extensive  
literature search. Relevant studies from five popular databases were identified using a comprehensive  
search strategy. An additional strength is that sensitivity tests were implemented to identify influential 
studies, which is important because inclusion of influential studies can lead to inaccurate conclusions. 
We also acknowledge the limitations of this literature review and meta-analysis. Despite a thorough 
search strategy, unavailable studies may exist which have not been included in the review. Because of a 
limited number of studies, it was not possible to assess publication bias over all metabolic and  
endocrine parameters, which limits our ability to perform subgroup analyses and attenuates the power 
of analyses. Included vitamin D intervention studies are subject to several limitations. On the one hand, 
most of the vitamin D supplementation studies were not randomized designs and were conducted with 
relatively small sizes of subjects, which may jeopardize the statistical power and reliability of 
corresponding findings. On the other hand, dosage of vitamin D supplementation and patients’ baseline 
serum vitamin D levels varied from study to study, thereby, there is uncertainty that all patients were 
administered sufficient amount of vitamin D. Moreover, seasonal and latitudinal changes play crucial 
impacts on cutaneous synthesis of vitamin D because solar ultraviolet B (UVB) radiation is one of major 
sources of vitamin D for humans. However, selected intervention studies failed to adjust for the 
confounding effects caused by seasonal and latitudinal disparities. Therefore, caution should be applied 
in extrapolation of results from the intervention studies. A further limitation of the present study is the 
lack of standardized scales for assessment of the quality of included studies, therefore the summarized 
effect size estimates should be interpreted with caution. Statistically significant heterogeneity was found 
from the majority of analyses (approximately 80%) concerning correlation between 25(OH)D levels and 
biochemical parameters, which may result from unreported findings (e.g., some studies reported only 
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significant correlations) and/or unpublished literature. Finally, included studies varied in the definitions 
of VDD, which may impact the assessment of the role of VDD on metabolic and endocrine disorders  
in PCOS. For example, Patra et al. [61] and Velija-Asimi et al. [63] used 30 ng ml−1 and used 20 ng ml−1 
as the cutoff points for vitamin D deficiency, respectively. 
5. Conclusions 
VDD is common among women affected by PCOS. If VDD were causally related to PCOS and the 
subsequent development of metabolic and hormonal dysfunction in PCOS, vitamin D supplementation 
would be a promising alternative for the prevention and treatment of PCOS. Meta-analysis of  
cross-sectional/case-control studies supports the existence of positive associations between VDD and 
metabolic and endocrine disorders in PCOS. Prospective observational studies that investigate the 
temporal relationship between VDD and PCOS are lacking. Our meta-analysis of intervention studies 
does not suggest a beneficial effect of vitamin D supplementation on metabolic and endocrine functions 
in women with PCOS despite the association noted in cross-sectional and case-control studies. Our 
review and meta-analysis therefore suggests that there is limited to no evidence that VDD is causally 
linked to development of PCOS. In light of this, we conclude that dysregulation of vitamin D metabolism 
may be a consequence of PCOS. Alternatively, VDD may be a common comorbid manifestation  
of PCOS. However, we cannot rule out the possibility that VDD may be a minor pathway towards PCOS 
given the small size of intervention studies and the variability of results from them. This review 
highlights a need for larger prospective studies in a well characterized sample of women with and 
without PCOS. Future studies should include multiple assessments of vitamin D in women at various stages 
of PCOS (if possible) to enhance our understanding of the temporal order of VDD in relation to PCOS, i.e., 
is VDD as a determinant of PCOS metabolic and hormonal dysregulations, a consequence of PCOS 
metabolic and hormonal dysregulations, or both? 
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